The drug induced a 100 percent reduction in symptomatic infection, as well as decreased overall infection rates by about half. The findings are based on preliminary analysis of a clinical trial run by the National Institute of Allergy and Infectious Disease in which 400 participants were exposed to a household member with COVID-19.
The treatment is a combination of casirivimab and imdevimab, two antibodies that fight against COVID-19. The FDA granted it emergency use authorization Nov. 21, allowing the antibody cocktail, which is administered intravenously as a one-time treatment, to be used in COVID-19 patients age 12 and over who weigh at least 88 pounds and have a high risk of their case becoming severe.
The U.S. on Jan. 12 agreed to buy up to 1.25 million doses of the antibody drug in a deal worth up to $2.6 billion.
Regenron’s announcement comes five days after Eli Lilly made a similar announcement about its antibody drug bamlanivimab, saying preliminary analysis showed it significantly reduced the risk of contracting symptomatic COVID-19 in residents and staff of long-term care facilities.
More articles on pharmacy:
CivicaRx to build drug manufacturing facility in Virginia
CVS says it’s completed first-round COVID-19 shots for skilled nursing facilities
White House: States can’t buy COVID-19 vaccines directly from drugmakers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
